Allosteric modulators of rhodopsin-like G protein-coupled receptors

Opportunities in drug development

Christa E. Müller, Anke C. Schiedel, Younis Baqi

Research output: Contribution to journalArticle

44 Citations (Scopus)

Abstract

Rhodopsin-like (class A) G protein-coupled receptors (GPCRs) are one of the most important classes of drug targets. The discovery that these GPCRs can be allosterically modulated by small drug molecules has opened up new opportunities in drug development. It will allow the drugability of difficult targets, such as GPCRs activated by large (glyco)proteins, or by very polar or highly lipophilic physiological agonists. Receptor subtype selectivity should be more easily achievable with allosteric than with orthosteric ligands. Allosteric modulation will allow a broad spectrum of pharmacological effects largely expanding that of orthosteric ligands. Furthermore, allosteric modulators may show an improved safety profile as compared to orthosteric ligands. Only recently, the explicit search for allosteric modulators has been started for only a few rhodopsin-like GPCRs. The first negative allosteric modulators (allosteric antagonists) of chemokine receptors, maraviroc (CCR5 receptor), used in HIV therapy, and plerixafor (CXCR4 receptor) for stem cell mobilization, have been approved as drugs. The development of allosteric modulators for rhodopsin-like GPCRs as novel drugs is still at an early stage; it appears highly promising.

Original languageEnglish
Pages (from-to)292-315
Number of pages24
JournalPharmacology and Therapeutics
Volume135
Issue number3
DOIs
Publication statusPublished - Sep 2012

Fingerprint

Rhodopsin
G-Protein-Coupled Receptors
Pharmaceutical Preparations
Ligands
CCR5 Receptors
Hematopoietic Stem Cell Mobilization
CXCR4 Receptors
Chemokine Receptors
HIV
Pharmacology
Safety
Proteins

Keywords

  • Ago-allosteric modulators
  • Allosteric agonists
  • Biased signaling
  • Negative allosteric modulators
  • Positive allosteric modulators

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Allosteric modulators of rhodopsin-like G protein-coupled receptors : Opportunities in drug development. / Müller, Christa E.; Schiedel, Anke C.; Baqi, Younis.

In: Pharmacology and Therapeutics, Vol. 135, No. 3, 09.2012, p. 292-315.

Research output: Contribution to journalArticle

@article{bc58abedab18497296337991228b47f0,
title = "Allosteric modulators of rhodopsin-like G protein-coupled receptors: Opportunities in drug development",
abstract = "Rhodopsin-like (class A) G protein-coupled receptors (GPCRs) are one of the most important classes of drug targets. The discovery that these GPCRs can be allosterically modulated by small drug molecules has opened up new opportunities in drug development. It will allow the drugability of difficult targets, such as GPCRs activated by large (glyco)proteins, or by very polar or highly lipophilic physiological agonists. Receptor subtype selectivity should be more easily achievable with allosteric than with orthosteric ligands. Allosteric modulation will allow a broad spectrum of pharmacological effects largely expanding that of orthosteric ligands. Furthermore, allosteric modulators may show an improved safety profile as compared to orthosteric ligands. Only recently, the explicit search for allosteric modulators has been started for only a few rhodopsin-like GPCRs. The first negative allosteric modulators (allosteric antagonists) of chemokine receptors, maraviroc (CCR5 receptor), used in HIV therapy, and plerixafor (CXCR4 receptor) for stem cell mobilization, have been approved as drugs. The development of allosteric modulators for rhodopsin-like GPCRs as novel drugs is still at an early stage; it appears highly promising.",
keywords = "Ago-allosteric modulators, Allosteric agonists, Biased signaling, Negative allosteric modulators, Positive allosteric modulators",
author = "M{\"u}ller, {Christa E.} and Schiedel, {Anke C.} and Younis Baqi",
year = "2012",
month = "9",
doi = "10.1016/j.pharmthera.2012.06.002",
language = "English",
volume = "135",
pages = "292--315",
journal = "Pharmacology and Therapeutics",
issn = "0163-7258",
publisher = "Elsevier Inc.",
number = "3",

}

TY - JOUR

T1 - Allosteric modulators of rhodopsin-like G protein-coupled receptors

T2 - Opportunities in drug development

AU - Müller, Christa E.

AU - Schiedel, Anke C.

AU - Baqi, Younis

PY - 2012/9

Y1 - 2012/9

N2 - Rhodopsin-like (class A) G protein-coupled receptors (GPCRs) are one of the most important classes of drug targets. The discovery that these GPCRs can be allosterically modulated by small drug molecules has opened up new opportunities in drug development. It will allow the drugability of difficult targets, such as GPCRs activated by large (glyco)proteins, or by very polar or highly lipophilic physiological agonists. Receptor subtype selectivity should be more easily achievable with allosteric than with orthosteric ligands. Allosteric modulation will allow a broad spectrum of pharmacological effects largely expanding that of orthosteric ligands. Furthermore, allosteric modulators may show an improved safety profile as compared to orthosteric ligands. Only recently, the explicit search for allosteric modulators has been started for only a few rhodopsin-like GPCRs. The first negative allosteric modulators (allosteric antagonists) of chemokine receptors, maraviroc (CCR5 receptor), used in HIV therapy, and plerixafor (CXCR4 receptor) for stem cell mobilization, have been approved as drugs. The development of allosteric modulators for rhodopsin-like GPCRs as novel drugs is still at an early stage; it appears highly promising.

AB - Rhodopsin-like (class A) G protein-coupled receptors (GPCRs) are one of the most important classes of drug targets. The discovery that these GPCRs can be allosterically modulated by small drug molecules has opened up new opportunities in drug development. It will allow the drugability of difficult targets, such as GPCRs activated by large (glyco)proteins, or by very polar or highly lipophilic physiological agonists. Receptor subtype selectivity should be more easily achievable with allosteric than with orthosteric ligands. Allosteric modulation will allow a broad spectrum of pharmacological effects largely expanding that of orthosteric ligands. Furthermore, allosteric modulators may show an improved safety profile as compared to orthosteric ligands. Only recently, the explicit search for allosteric modulators has been started for only a few rhodopsin-like GPCRs. The first negative allosteric modulators (allosteric antagonists) of chemokine receptors, maraviroc (CCR5 receptor), used in HIV therapy, and plerixafor (CXCR4 receptor) for stem cell mobilization, have been approved as drugs. The development of allosteric modulators for rhodopsin-like GPCRs as novel drugs is still at an early stage; it appears highly promising.

KW - Ago-allosteric modulators

KW - Allosteric agonists

KW - Biased signaling

KW - Negative allosteric modulators

KW - Positive allosteric modulators

UR - http://www.scopus.com/inward/record.url?scp=84864462348&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84864462348&partnerID=8YFLogxK

U2 - 10.1016/j.pharmthera.2012.06.002

DO - 10.1016/j.pharmthera.2012.06.002

M3 - Article

VL - 135

SP - 292

EP - 315

JO - Pharmacology and Therapeutics

JF - Pharmacology and Therapeutics

SN - 0163-7258

IS - 3

ER -